|
|
| (5 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| | | #REDIRECT [[talk:Cariprazine]] |
| {{decree|type=notice|message=This article is in the 'Talk' namespace because it is an unfinished draft. This section is used to host drafts for unpublished articles as well as discussions for published ones. If you'd like to use this area to discuss this draft, please do so in the 'Discussion' section at the very bottom of the page. This notice will be removed once this draft has been approved for publication by an administrator.}}
| |
| | |
| {{headerpanel|{{Approval}}}}
| |
| {{SummarySheet}}
| |
| {{SubstanceBox/Example}}
| |
| | |
| <!-- Please ensure that any new substance articles are first published in the 'Talk' namespace. For example, a new article on substance XYZ should have the title "Talk: XYZ" instead of "XYZ". Once the submitted article has been reviewed and determined to meet the guidelines and standards, it will be published by a staff member. -->
| |
| | |
| For tips on how to properly format a substance article, please refer to this document: [[Content Style Guide - Substance]]
| |
| | |
| ==History and culture==
| |
| Cariprazine is used to treat patients with schizophrenia and manic, depressive, or mixed episodes associated with bipolar I disorder. In the United States it is approved for schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and treatment of depressive episodes associated with bipolar I disorder (bipolar depression).
| |
| | |
| Cariprazine consistently improved depressive symptoms across a spectrum of patients with bipolar I depression. In Australia, the United Kingdom, and the European Union it is approved only for treating schizophrenia.
| |
| | |
| ==Chemistry==
| |
| Cariprazine, sold under the brand names Vraylar and Reagila among others, is an atypical antipsychotic originated by Gedeon Richter, which is used in the treatment of schizophrenia, bipolar mania, bipolar depression, and major depressive disorder. It acts primarily as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. Cariprazine is also a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors, with high selectivity for the D3 receptor.[ It is taken by mouth.
| |
| | |
| ==Pharmacology==
| |
| {{pharmacology}}
| |
| | |
| ==Subjective effects==
| |
| {{EffectStub}}
| |
| {{Preamble/SubjectiveEffects}}
| |
| {{effects/base
| |
| | |
| |{{effects/physical|
| |
| If applicable, a brief paragraph summary of the substance's physical effects may be included here.
| |
| | |
| You may select physical effects to add below [[Subjective effect index#Physical effects|here]].
| |
| | |
| *'''[[Effect::Physical effect]]'''
| |
| *'''[[Effect::Physical effect2]]'''
| |
| *'''[[Effect::Physical effect3]]'''
| |
| | |
| }}
| |
| {{effects/visual|
| |
| If applicable, a brief paragraph summary of the substance's visual effects may be included here.
| |
| | |
| You may select visual effects to add below [[Subjective effect index#Visual effects|here]].
| |
| | |
| ====Enhancements====
| |
| *'''[[Effect::Visual acuity effect1]]'''
| |
| | |
| ====Distortions====
| |
| *'''[[Effect::Visual distortion effect1]]'''
| |
| | |
| ====[[Effect::Geometry]]====
| |
| If applicable, a brief paragraph summary describing the visual geometry produced by the substance may be included here.
| |
| ====Hallucinatory states====
| |
| If applicable, a brief summary of the substance's visual effects profile may be written here.
| |
| | |
| *'''[[Effect::Hallucinatory states1]]'''
| |
| | |
| }}
| |
| | |
| |{{effects/cognitive|
| |
| If applicable, a brief paragraph summary of the substance's cognitive effects may be included here.
| |
| | |
| You may select from a list of cognitive effects to add below [[Subjective effect index#Cognitive effects|here]].
| |
| | |
| *'''[[Effect::Cognitive effect1]]'''
| |
| *'''[[Effect::Cognitive effect2]]'''
| |
| *'''[[Effect::Cognitive effect3]]'''
| |
| | |
| }}
| |
| {{effects/auditory|
| |
| If applicable, a brief paragraph summary of the substance's auditory effects may be included here.
| |
| | |
| You may select from a list of auditory effects to add below [[Subjective effect index#Auditory effects|here]].
| |
| | |
| *'''[[Effect::Auditory effect1]]'''
| |
| *'''[[Effect::Auditory effect2]]'''
| |
| | |
| }}
| |
| {{effects/multisensory|
| |
| If applicable, a brief paragraph summary of the substance's multisensory effects may be included here.
| |
| | |
| You may select from a list of multisensory effects to add below [[Subjective effect index#Multisensory effects|here]].
| |
| | |
| *'''[[Effect::Multisensory effect1]]'''
| |
| *'''[[Effect::Multisensory effect2]]'''
| |
| | |
| }}
| |
| {{effects/transpersonal|
| |
| If applicable, a brief paragraph summary of the substance's transpersonal effects may be included here.
| |
| | |
| You may select from a list of transpersonal effects to add below [[Subjective effect index#Transpersonal effects|here]].
| |
| | |
| *'''[[Effect::Transpersonal effect1]]'''
| |
| *'''[[Effect::Transpersonal effect2]]'''
| |
| | |
| }}
| |
| }}
| |
| ===Experience reports===
| |
| There are currently {{#ask:[[Category:SUBSTANCE]][[Category:Experience]] | format=count}} experience reports which describe the effects of this substance in our [[experience index]].
| |
| {{#ask: [[Category:SUBSTANCE]][[Category:Experience]]|format=ul|Columns=1}}
| |
| Additional experience reports can be found here:
| |
| * [https://www.erowid.org/experiences/subs/exp_SUBSTANCE.shtml Erowid Experience Vaults: SUBSTANCE] <!-- Check the link to see if it exists -->
| |
| | |
| ==Toxicity and harm potential==
| |
| {{toxicity}}
| |
| It is strongly recommended that one use [[responsible use|harm reduction practices]] when using this substance.
| |
| ===Lethal dosage===
| |
| ===Tolerance and addiction potential===
| |
| ===Dangerous interactions===
| |
| {{DangerousInteractions}}
| |
| {{DangerousInteractions/Intro}}
| |
| | |
| ==Legal status==
| |
| {{LegalStub}}
| |
| | |
| ==See also==
| |
| *[[Responsible use]]
| |
| | |
| ==External links==
| |
| (List along order below)
| |
| * [https://en.wikipedia.org/wiki/SUBSTANCE SUBSTANCE (Wikipedia)]
| |
| * SUBSTANCE (Erowid Vault)
| |
| * SUBSTANCE ([''PiHKAL'' or ''TiHKAL''] / Isomer Design)
| |
| | |
| ==Literature==
| |
| * APA formatted reference
| |
| | |
| Please see the [[citation formatting guide]] if you need assistance properly formatting citations.
| |
| | |
| ==References==
| |
| <references />
| |
| | |
| [[Category:Psychoactive substance]][[Category:Proofread]][[Category:Approval]]
| |
